# ELAINE 3 (NCT05696626)

> Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

No report yet. It can be ordered.

- Drugs tested: lasofoxifene plus abemaciclib
- Indication: ESR1-mutated ER+/HER2- locally advanced or metastatic breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05696626
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: LeonaBio
- Conditions: Metastatic Breast Cancer
- Interventions: Lasofoxifene in combination with abemaciclib; Fulvestrant in combination with abemaciclib
- Enrollment: 600
- Primary outcome: Progression free survival (PFS)

## Indexed commentary on ELAINE 3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 6
- Podcasts: 5
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=elaine-3-nct05696626

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05696626", "email": "<work email>"}; the inbox owner confirms by the emailed link.